Document Detail

Albumin utilization in cardiac surgery after transition to hydroxyethyl starch 130/0.4.
MedLine Citation:
PMID:  22797837     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Evaluate the impact of replacing hydroxyethyl starch (HES) 670/0.75 with lower molecular weight HES 130/0.4 on albumin utilization in cardiac surgery, as well as any impact on renal function and bleeding.
DESIGN: A pre- and postimplementation, retrospective analysis.
SETTING: Community, not-for-profit, tertiary medical center.
PARTICIPANTS: One hundred forty-six patients undergoing nonemergent cardiac bypass graft and cardiac valve surgeries after exclusion for documented anemia, malignancy, coagulation disorder, end-stage renal disease, or personal objection to receiving blood products.
INTERVENTION: HES 130/0.4 utilization instead of HES 670/0.75 for volume expansion.
MEASUREMENTS AND MAIN RESULTS: Patients were less likely to be administered albumin intraoperatively (odds ratio [OR] 0.16, confidence interval [CI] 0.08-0.35, P < .001). When albumin was utilized, intraoperative amounts were similar (mean ± standard deviation [SD]: 36.1 ± 17.1 g vs 43.8 ± 15.5 g, P = .16). Patients were more likely to receive an intraoperative HES product after the formulary change (OR 11.1, CI 4.4-27.6, P < .001) as well as larger volumes (mean ± SD: 743 ± 544 mL vs 500 ± 0 mL, P = .01). No differences were detected in mean baseline-to-discharge changes in serum creatinine or in postoperative urine output, nor were there differences in clinically significant bleeding.
CONCLUSIONS: Change to a lower molecular weight HES decreased intraoperative albumin utilization and increased HES utilization with no detected difference in renal function or bleeding complications.
David B Romerill; Alexander Y Toyoda; Brandon E Brodeur; Daniel Moellentin
Related Documents :
23477927 - German aortic valve score: a new scoring system for prediction of mortality related to ...
25143637 - High sensitive c-reactive protein-effective tool in determining postoperative recovery ...
24396227 - Comparable short-term results seen with standard and high-flexion knee arthroplasty des...
3148127 - Topical mupirocin vs. systemic erythromycin treatment for pyoderma.
8242317 - Initial report from a swedish multicentre study examining the role of preoperative irra...
3046167 - Primary megaureter in the neonate with prenatal or postnatal diagnosis.
Publication Detail:
Type:  Journal Article     Date:  2012-07-13
Journal Detail:
Title:  Journal of pharmacy practice     Volume:  25     ISSN:  1531-1937     ISO Abbreviation:  J Pharm Pract     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-11     Completed Date:  2013-05-21     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  8900945     Medline TA:  J Pharm Pract     Country:  United States    
Other Details:
Languages:  eng     Pagination:  606-10     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Albumins / administration & dosage*,  adverse effects
Cardiac Surgical Procedures / adverse effects,  methods*,  standards
Hydroxyethyl Starch Derivatives / administration & dosage*,  adverse effects
Middle Aged
Plasma Substitutes / administration & dosage*,  adverse effects
Postoperative Complications / prevention & control
Retrospective Studies
Treatment Outcome
Reg. No./Substance:
0/Albumins; 0/Hydroxyethyl Starch Derivatives; 0/Plasma Substitutes

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Practices Associated with Serum Antiepileptic Drug Level Monitoring at a Pediatric Neurology Clinic:...
Next Document:  Maximal exercise performance in patients with postcancer fatigue.